BACKGROUND: Male circumcision reduces the transmission of high-risk human papillomavirus (HPV) in HIV-uninfected men and their female partners. We assessed whether circumcision of HIV-infected men would reduce the transmission of high-risk HPV to their female partners. METHODS:Female partners of HIV-infected men (aged 15-49 years) in Rakai, Uganda, with CD4 counts of greater than 350 cells per mL who were randomly assigned to undergo circumcision immediately (intervention group) and after 24 months (control group) were assessed for infection with high-risk HPV. Randomisation was done in blocks of 20, stratified by community, with computer-generated random numbers. Laboratory technicians and female fieldworkers were masked to the circumcision status of male participants. The main outcome assessed in this study was the effects of circumcision of HIV-infected men on transmission of HPV to their female partners. Analysis was by intention to treat. The trial is registered with ClinicalTrials.gov, number NCT00124878. FINDINGS:474 men were assigned to the intervention group, 448 to the control group. 211 women were in consensual relationships with 193 men in the intervention group, and 171 women were in consensual unions with 155 men in the control group. High-risk HPV at the 2-year follow-up was prevalent in 88 female partners (55%) of 159 men in the intervention group and 68 (52%) of 131 female partners of men in the control group (prevalence risk ratio 1·07, 95% CI 0·86-1·32, p=0·64). Incidence of high-risk HPV over 2 years was 32·0 per 100 person-years in the female partners of men in the intervention group and 30·6 per 100 person-years in the female partners of men in the control group (incidence rate ratio 1·05, 0·77-1·43, p=0·78). No difference was noted in the clearance of genotype-specific high-risk HPV between the intervention group (196 [46%] of 424) and control group (167 [48%] of 347; rate ratio 0·96, 0·83-1·12; p=0·61). INTERPRETATION: Because circumcision of HIV-infected men did not affect transmission of high-risk HPV to their female partners, promotion of consistent safe sexual practices for HIV-infected men remains important. FUNDING: Bill & Melinda Gates Foundation and National Institutes of Health.
RCT Entities:
BACKGROUND: Male circumcision reduces the transmission of high-risk human papillomavirus (HPV) in HIV-uninfectedmen and their female partners. We assessed whether circumcision of HIV-infectedmen would reduce the transmission of high-risk HPV to their female partners. METHODS: Female partners of HIV-infectedmen (aged 15-49 years) in Rakai, Uganda, with CD4 counts of greater than 350 cells per mL who were randomly assigned to undergo circumcision immediately (intervention group) and after 24 months (control group) were assessed for infection with high-risk HPV. Randomisation was done in blocks of 20, stratified by community, with computer-generated random numbers. Laboratory technicians and female fieldworkers were masked to the circumcision status of male participants. The main outcome assessed in this study was the effects of circumcision of HIV-infectedmen on transmission of HPV to their female partners. Analysis was by intention to treat. The trial is registered with ClinicalTrials.gov, number NCT00124878. FINDINGS: 474 men were assigned to the intervention group, 448 to the control group. 211 women were in consensual relationships with 193 men in the intervention group, and 171 women were in consensual unions with 155 men in the control group. High-risk HPV at the 2-year follow-up was prevalent in 88 female partners (55%) of 159 men in the intervention group and 68 (52%) of 131 female partners of men in the control group (prevalence risk ratio 1·07, 95% CI 0·86-1·32, p=0·64). Incidence of high-risk HPV over 2 years was 32·0 per 100 person-years in the female partners of men in the intervention group and 30·6 per 100 person-years in the female partners of men in the control group (incidence rate ratio 1·05, 0·77-1·43, p=0·78). No difference was noted in the clearance of genotype-specific high-risk HPV between the intervention group (196 [46%] of 424) and control group (167 [48%] of 347; rate ratio 0·96, 0·83-1·12; p=0·61). INTERPRETATION: Because circumcision of HIV-infectedmen did not affect transmission of high-risk HPV to their female partners, promotion of consistent safe sexual practices for HIV-infectedmen remains important. FUNDING: Bill & Melinda Gates Foundation and National Institutes of Health.
Authors: G S Ogilvie; D M Patrick; M Schulzer; J W Sellors; M Petric; K Chambers; R White; J M FitzGerald Journal: Sex Transm Infect Date: 2005-06 Impact factor: 3.519
Authors: S K Kjaer; E M de Villiers; C Dahl; G Engholm; J E Bock; B F Vestergaard; E Lynge; O M Jensen Journal: Int J Cancer Date: 1991-04-22 Impact factor: 7.396
Authors: Howard D Strickler; Robert D Burk; Melissa Fazzari; Kathryn Anastos; Howard Minkoff; L Stewart Massad; Charles Hall; Melanie Bacon; Alexandra M Levine; D Heather Watts; Michael J Silverberg; Xiaonan Xue; Nicolas F Schlecht; Sandra Melnick; Joel M Palefsky Journal: J Natl Cancer Inst Date: 2005-04-20 Impact factor: 13.506
Authors: Rebecca G Nowak; Patti E Gravitt; Charles S Morrison; Stephen J Gange; Cynthia Kwok; Amy E Oliver; Roslyn Howard; Barbara Van der Pol; Robert A Salata; Nancy S Padian; Tsungai Chipato; Marshall Munjoma; David D Celentano Journal: J Infect Dis Date: 2011-04-15 Impact factor: 5.226
Authors: Tiffany G Harris; Robert D Burk; Joel M Palefsky; L Stewart Massad; Ji Yon Bang; Kathryn Anastos; Howard Minkoff; Charles B Hall; Melanie C Bacon; Alexandra M Levine; D Heather Watts; Michael J Silverberg; Xiaonan Xue; Sandra L Melnick; Howard D Strickler Journal: JAMA Date: 2005-03-23 Impact factor: 56.272
Authors: D Serwadda; M J Wawer; K V Shah; N K Sewankambo; R Daniel; C Li; A Lorincz; M P Meehan; F Wabwire-Mangen; R H Gray Journal: J Infect Dis Date: 1999-10 Impact factor: 5.226
Authors: Xavier Castellsagué; F Xavier Bosch; Nubia Muñoz; Chris J L M Meijer; Keerti V Shah; Silvia de Sanjose; José Eluf-Neto; Corazon A Ngelangel; Saibua Chichareon; Jennifer S Smith; Rolando Herrero; Victor Moreno; Silvia Franceschi Journal: N Engl J Med Date: 2002-04-11 Impact factor: 91.245
Authors: L A Brinton; W C Reeves; M M Brenes; R Herrero; E Gaitan; F Tenorio; R C de Britton; M Garcia; W E Rawls Journal: Int J Cancer Date: 1989-08-15 Impact factor: 7.396
Authors: Aaron A R Tobian; Godfrey Kigozi; Andrew D Redd; David Serwadda; Xiangrong Kong; Amy Oliver; Fred Nalugoda; Thomas C Quinn; Ronald H Gray; Maria J Wawer Journal: J Infect Dis Date: 2011-12-05 Impact factor: 5.226
Authors: Virginia Senkomago; Danielle M Backes; Michael G Hudgens; Charles Poole; Kawango Agot; Stephen Moses; Peter J F Snijders; Chris J L M Meijer; Albertus T Hesselink; Nicolas F Schlecht; Robert C Bailey; Jennifer S Smith Journal: J Infect Dis Date: 2014-09-26 Impact factor: 5.226
Authors: Mary K Grabowski; Patti E Gravitt; Ronald H Gray; David Serwadda; Andrew D Redd; Godfrey Kigozi; Xiangrong Kong; Fred Nalugoda; Maria J Wawer; Thomas C Quinn; Aaron A R Tobian Journal: J Infect Dis Date: 2017-03-01 Impact factor: 5.226
Authors: Sten H Vermund; José A Tique; Holly M Cassell; Megan E Pask; Philip J Ciampa; Carolyn M Audet Journal: J Acquir Immune Defic Syndr Date: 2013-06-01 Impact factor: 3.731
Authors: Aaron A R Tobian; Mary K Grabowski; Godfrey Kigozi; Andrew D Redd; Kevin P Eaton; David Serwadda; Toby C Cornish; Fred Nalugoda; Stephen Watya; Denis Buwembo; James Nkale; Maria J Wawer; Thomas C Quinn; Ronald H Gray Journal: J Infect Dis Date: 2013-01-23 Impact factor: 5.226
Authors: Jeanne M Marrazzo; Carlos del Rio; David R Holtgrave; Myron S Cohen; Seth C Kalichman; Kenneth H Mayer; Julio S G Montaner; Darrell P Wheeler; Robert M Grant; Beatriz Grinsztejn; N Kumarasamy; Steven Shoptaw; Rochelle P Walensky; Francois Dabis; Jeremy Sugarman; Constance A Benson Journal: JAMA Date: 2014 Jul 23-30 Impact factor: 56.272